Retatrutide (LY3437943) is an investigational unimolecular peptide that acts as an agonist at three distinct receptors: the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple agonism distinguishes it from other incretin-based therapies that typically target one or two of these pathways. Developed by Eli Lilly and Company, Retatrutide is currently undergoing clinical trials primarily for the treatment of obesity and related metabolic conditions, including type 2 diabetes. Its unique multimodal action is hypothesized to lead to enhanced effects on body weight reduction and glycemic control compared to single- or dual-agonist approaches. Clinical studies have explored its efficacy and safety profile across various populations, aiming to establish its potential role in managing chronic metabolic diseases. As an injectable peptide, its administration is typically subcutaneous. Information regarding Retatrutide is primarily derived from clinical trial reports and scientific publications, as it is not yet approved for clinical use (Eli Lilly Clinical Trials, scientific literature).
Deep dive
Tap a section to expand.
Known interactions
Category rule: glp1 × supplement
Note
GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.
Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider.
Compound-pair rule
Caution
Combining a GLP-1 with rapid insulin increases hypoglycemia risk.
Reduce mealtime insulin at GLP-1 initiation; monitor glucose closely.
Compound-pair rule
Caution
GLP-1 plus basal insulin increases hypoglycemia risk.
Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate.
Frequently asked
Sources referenced
* Clinical trial data from Eli Lilly and Company (Eli Lilly Clinical Trials website and presentations)
* PubChem
* DrugBank
* Peer-reviewed scientific journals (e.g., New England Journal of Medicine, The Lancet Diabetes & Endocrinology)
* FDA drug labels for similar GLP-1 receptor agonists
* MedlinePlus
* National Institutes of Health (NIH) resources
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the glp1 category or studied for the same goals.
